301 related articles for article (PubMed ID: 15064027)
1. Responsiveness to a pandemic alert: use of reverse genetics for rapid development of influenza vaccines.
Webby RJ; Perez DR; Coleman JS; Guan Y; Knight JH; Govorkova EA; McClain-Moss LR; Peiris JS; Rehg JE; Tuomanen EI; Webster RG
Lancet; 2004 Apr; 363(9415):1099-103. PubMed ID: 15064027
[TBL] [Abstract][Full Text] [Related]
2. Development of a new candidate H5N1 avian influenza virus for pre-pandemic vaccine production.
Dong J; Matsuoka Y; Maines TR; Swayne DE; O'Neill E; Davis CT; Van-Hoven N; Balish A; Yu HJ; Katz JM; Klimov A; Cox N; Li DX; Wang Y; Guo YJ; Yang WZ; Donis RO; Shu YL
Influenza Other Respir Viruses; 2009 Nov; 3(6):287-95. PubMed ID: 19903211
[TBL] [Abstract][Full Text] [Related]
3. Preparation of genetically engineered A/H5N1 and A/H7N1 pandemic vaccine viruses by reverse genetics in a mixture of Vero and chicken embryo cells.
Legastelois I; Garcia-Sastre A; Palese P; Tumpey TM; Maines TR; Katz JM; Vogel FR; Moste C
Influenza Other Respir Viruses; 2007 May; 1(3):95-104. PubMed ID: 19453414
[TBL] [Abstract][Full Text] [Related]
4. Development and comparison of two H5N8 influenza A vaccine candidate strains.
Lee MS; Jang EY; Cho J; Kim K; Lee CH; Yi H
Arch Virol; 2019 Jan; 164(1):127-136. PubMed ID: 30291503
[TBL] [Abstract][Full Text] [Related]
5. Experimental challenge of chicken vaccinated with commercially available H5 vaccines reveals loss of protection to some highly pathogenic avian influenza H5N1 strains circulating in Hong Kong/China.
Connie Leung YH; Luk G; Sia SF; Wu YO; Ho CK; Chow KC; Tang SC; Guan Y; Malik Peiris JS
Vaccine; 2013 Aug; 31(35):3536-42. PubMed ID: 23791547
[TBL] [Abstract][Full Text] [Related]
6. Generation of a reassortant avian influenza virus H5N2 vaccine strain capable of protecting chickens against infection with Egyptian H5N1 and H9N2 viruses.
Kandeil A; Moatasim Y; Gomaa MR; Shehata MM; El-Shesheny R; Barakat A; Webby RJ; Ali MA; Kayali G
Vaccine; 2016 Jan; 34(2):218-224. PubMed ID: 26620838
[TBL] [Abstract][Full Text] [Related]
7. Generation of candidate human influenza vaccine strains in cell culture - rehearsing the European response to an H7N1 pandemic threat.
Whiteley A; Major D; Legastelois I; Campitelli L; Donatelli I; Thompson CI; Zambon MC; Wood JM; Barclay WS
Influenza Other Respir Viruses; 2007 Jul; 1(4):157-66. PubMed ID: 19432631
[TBL] [Abstract][Full Text] [Related]
8. Generation and evaluation of an H9N1 influenza vaccine derived by reverse genetics that allows utilization of a DIVA strategy for control of H9N2 avian influenza.
Wu R; Chen Q; Zheng L; Chen J; Sui Z; Guan Y; Chen Z
Arch Virol; 2009; 154(8):1203-10. PubMed ID: 19543688
[TBL] [Abstract][Full Text] [Related]
9. Protective efficacy of a high-growth reassortant H1N1 influenza virus vaccine against the European Avian-like H1N1 swine influenza virus in mice and pigs.
Ruan BY; Wen F; Gong XQ; Liu XM; Wang Q; Yu LX; Wang SY; Zhang P; Yang HM; Shan TL; Zheng H; Zhou YJ; Tong W; Gao F; Tong GZ; Yu H
Vet Microbiol; 2018 Aug; 222():75-84. PubMed ID: 30080677
[TBL] [Abstract][Full Text] [Related]
10. Evaluation of avian influenza virus isolated from ducks as a potential live vaccine candidate against novel H7N9 viruses.
Jiang WM; Wang SC; Liu HL; Yu JM; Du X; Hou GY; Li JP; Liu S; Wang KC; Zhuang QY; Liu XM; Chen JM
Vaccine; 2014 Nov; 32(48):6433-9. PubMed ID: 25285880
[TBL] [Abstract][Full Text] [Related]
11. Evaluation of a genetically modified reassortant H5N1 influenza A virus vaccine candidate generated by plasmid-based reverse genetics.
Subbarao K; Chen H; Swayne D; Mingay L; Fodor E; Brownlee G; Xu X; Lu X; Katz J; Cox N; Matsuoka Y
Virology; 2003 Jan; 305(1):192-200. PubMed ID: 12504552
[TBL] [Abstract][Full Text] [Related]
12. Development and evaluation of an Influenza virus subtype H7N2 vaccine candidate for pandemic preparedness.
Pappas C; Matsuoka Y; Swayne DE; Donis RO
Clin Vaccine Immunol; 2007 Nov; 14(11):1425-32. PubMed ID: 17913860
[TBL] [Abstract][Full Text] [Related]
13. Optimized clade 2.3.2.1c H5N1 recombinant-vaccine strains against highly pathogenic avian influenza.
Jang JW; Lee CY; Kim IH; Choi JG; Lee YJ; Yuk SS; Lee JH; Song CS; Kim JH; Kwon HJ
J Vet Sci; 2017 Aug; 18(S1):299-306. PubMed ID: 28859269
[TBL] [Abstract][Full Text] [Related]
14. Broadening the H5N3 Vaccine Immunogenicity against H5N1 Virus by Modification of Neutralizing Epitopes.
Rajesh Kumar S; Chelvaretnam S; Tan Y; Prabakaran M
Viruses; 2017 Dec; 10(1):. PubMed ID: 29295514
[TBL] [Abstract][Full Text] [Related]
15. A live attenuated cold-adapted influenza A H7N3 virus vaccine provides protection against homologous and heterologous H7 viruses in mice and ferrets.
Joseph T; McAuliffe J; Lu B; Vogel L; Swayne D; Jin H; Kemble G; Subbarao K
Virology; 2008 Aug; 378(1):123-32. PubMed ID: 18585748
[TBL] [Abstract][Full Text] [Related]
16. Development of Eurasian H7N7/PR8 high growth reassortant virus for clinical evaluation as an inactivated pandemic influenza vaccine.
Jadhao SJ; Achenbach J; Swayne DE; Donis R; Cox N; Matsuoka Y
Vaccine; 2008 Mar; 26(14):1742-50. PubMed ID: 18336962
[TBL] [Abstract][Full Text] [Related]
17. Strategies for developing vaccines against H5N1 influenza A viruses.
Horimoto T; Kawaoka Y
Trends Mol Med; 2006 Nov; 12(11):506-14. PubMed ID: 17011235
[TBL] [Abstract][Full Text] [Related]
18. Assessment of national strategies for control of high-pathogenicity avian influenza and low-pathogenicity notifiable avian influenza in poultry, with emphasis on vaccines and vaccination.
Swayne DE; Pavade G; Hamilton K; Vallat B; Miyagishima K
Rev Sci Tech; 2011 Dec; 30(3):839-70. PubMed ID: 22435196
[TBL] [Abstract][Full Text] [Related]
19. Protective Efficacy of an H5N1 Inactivated Vaccine Against Challenge with Lethal H5N1, H5N2, H5N6, and H5N8 Influenza Viruses in Chickens.
Zeng X; Chen P; Liu L; Deng G; Li Y; Shi J; Kong H; Feng H; Bai J; Li X; Shi W; Tian G; Chen H
Avian Dis; 2016 May; 60(1 Suppl):253-5. PubMed ID: 27309064
[TBL] [Abstract][Full Text] [Related]
20. Characterization of an influenza A H5N2 reassortant as a candidate for live-attenuated and inactivated vaccines against highly pathogenic H5N1 viruses with pandemic potential.
Desheva JA; Lu XH; Rekstin AR; Rudenko LG; Swayne DE; Cox NJ; Katz JM; Klimov AI
Vaccine; 2006 Nov; 24(47-48):6859-66. PubMed ID: 17050041
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
